This table, the fifth of five parts (earlier parts were in the July 10, July 25, Aug. 25, and Sept. 10 issues), is adapted and excerpted from the latest Pharmaceutical Research and Manufacturers of America survey of Medicines in Development for Cancer. Of the 399 medicines in development by the National Cancer Institute and 178 pharmaceutical and biotechnology companies, 62 are for lung cancer, 49 for breast cancer, 50 for prostate cancer, 35 for colon cancer, six for bladder cancer, 25 for brain cancer, 13 for cervical cancer, 15 for head and neck cancer, 26 for kidney cancer, 52 for leukemia, 13 for liver cancer, 51 for lymphomas, 20 for myeloma, three for neuroblastoma, 21 for ovarian cancer, 25 for pancreatic cancer, eight for sarcoma, 39 for skin cancer, 85 for various solid tumors, 15 for stomach cancer, 24 for cancer-related conditions, and 49 for other and unspecified cancers. The chart shows the name of each product, the company/organization involved, the indication, and the development status as of the time of the report this spring, and a contact telephone number to request further information.
© 2005 Lippincott Williams & Wilkins, Inc.
More on ONCOLOGY-TIMES.com...